Diagnosis, Treatment, and Prevention of Urinary Tract Infection.

UTI may involve the lower or upper urinary tract and may be uncomplicated or complicated. The emphasis of this chapter is uncomplicated UTI. The diagnosis of uncomplicated cystitis (bladder infection) and pyelonephritis (kidney infection) is usually easily made based on the clinical presentation, whereas the diagnosis in patients with complicated UTI is often more complex. Thus uncomplicated cystitis is usually manifested by dysuria, frequency and/or urgency without fever, and pyelonephritis is usually manifested by fever and back pain/costovertebral angle tenderness. However, pyuria is usually present with UTI, regardless of location, and its absence suggests that another condition may be causing the patient's symptoms. Treatment of cystitis is usually straightforward with one of several effective short-course antimicrobial regimens, although antimicrobial resistance continues to increase and can complicate treatment choices in certain areas. Likewise, antimicrobial resistance has complicated our management of uncomplicated pyelonephritis since resistance of uropathogens to the fluoroquinolone class, the mainstay of oral treatment for pyelonephritis, is increasing worldwide, and some of the other agents used for cystitis are not recommended for pyelonephritis due to low tissue levels. The goal of prevention of recurrent cystitis is to minimize the use of antimicrobials and there are several research efforts in progress to develop effective and safe antimicrobial-sparing preventive approaches for this common condition.

New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.

INTRODUCTION: A key objective with highly active antiretroviral therapy for the treatment of HIV infection has been the optimization of antiretroviral drug combinations for individual patients. AREAS COVERED: Overall, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (in combination with two nucleoside reverse transcriptase inhibitors (NRTIs)) have become mainstays for initial ARV regimens. Early NNRTIs, efavirenz and nevirapine, are similarly efficacious, but differ according to their toxicity profiles. Newer NNRTIs, rilpivirine and etravirine are also efficacious. Etravirine was designed to overcome common first-line NNRTI resistance mutations, and serves as a second line agent. EXPERT OPINION: As a class, NNRTIs are key components of ARV regimens. Currently, there are 3 NNRTIs that may be used in first-line regimens, and one in second-line regimens. ARV regimen optimization depends on matching individual drug efficacy, safety, resistance, and toxicity profiles to particular patients. Once-daily dosing options are essential to treatment simplification strategies, which have been shown to enhance regimen compliance and durabiltiy. These are especially important due to the low genetic barrier to resistance generally associated with NNRTIs. As newer drugs are introduced, especially as part of once-daily, single-tablet regimens, this will expand the number of convenient and efficacious treatment options available.

Increase in lymphogranuloma venereum cases in South Florida.

The purpose of the study was to evaluate the clinic prevalence and clinical characteristics of patients with LGV since 2007 when active clinic surveillance started. We review all the reports of rectal Chlamydia trachomatis and LGV testing of those samples. Chlamydia trachomatis LGV DNA was detected by Nucleic Acid Amplification/ompA gene sequencing. Medical records of all patients with LGV were reviewed. Prevalence of rectal CT among tested individuals was relatively stable during the study period: 2007 (15%), 2008 (15%), 2009 (12%) and 2010 (14%). Eight cases of LGV were identified during the study period, one in 2009 and seven in 2010. All individuals were male and all except one had sex with only men. Most of them were also infected with HIV (62.5%). We concluded that this is the first report of LGV cases in South Florida and shows a rapid increase in the number of cases in the last year.

Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection in a patient with advanced HIV infection.

We describe a patient with advanced HIV infection and Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with Toxoplasma gondii coinfection. A multidisciplinary effort and state-of-the-art diagnostic techniques were required for diagnosis. Our patient is the first reported case of an HIV-infected person with dual Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection.